J&J seeking first-line MM indication for Darzalex

Johnson & Johnson (NYSE:JNJ) submitted applications in both the U.S. and EU seeking to push Darzalex daratumumab into the first-line setting to treat multiple myeloma.

On Tuesday, the pharma said it submitted an

Read the full 328 word article

User Sign In